Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 10/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327003 | 0.86 | HTR2C (0.36) | SIGMAR1KDM1A | |
| SCHEMBL13299028 | 0.82 | EPHX2 (0.36) | KDM1A | |
| SCHEMBL24650858 | 0.81 | PYGL (0.42) | SIGMAR1KDM1A | |
| Hydrochloric Acid SCHEMBL3328714 | 0.80 | PYGL (0.41) | SIGMAR1KDM1A | |
| SCHEMBL24650860 | 0.79 | PYGL (0.43) | SIGMAR1KDM1A | |
| SCHEMBL3327000 | 0.78 | ESR1 (0.35) | ALOX15 | |
| SCHEMBL24650472 | 0.78 | PYGL (0.44) | PTGDR2CD69SIGMAR1ALOX15KDM1A | |
| SCHEMBL24650851 | 0.77 | PYGL (0.45) | — | |
| SCHEMBL8654044 | 0.76 | GAA (0.46) | — | |
| SCHEMBL7337626 | 0.76 | GAA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | PYGL, PYGM, GYS2 | PTGIR 2476/4885PTGDR 3553/4885PTGDR2 3500/4885 |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | PTGIR 3725/4885PTGDR 4728/4885PTGDR2 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.